Who
John Oyler
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, BeOne Medicines.
In numbers
- Trades disclosed
- 971
- Buys
- 0
- Sells
- 125
- Bought
- $0
- Sold
- $1.1B
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Feb 2016
- Last trade
- 12 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $702K1,980 at $354.71 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $896K2,515 at $356.43 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $5.5M15,396 at $357.63 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $7.5M20,899 at $358.41 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $5.1M14,102 at $359.12 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $702K1,980 at $354.71 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $896K2,515 at $356.43 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $5.5M15,396 at $357.63 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $7.5M20,899 at $358.41 | filing |
| 12 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $5.1M14,102 at $359.12 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $4.9M13,695 at $359.32 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $2.9M8,081 at $360.33 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $5.3M14,569 at $361.47 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $4.2M11,568 at $362.34 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $4.9M13,403 at $363.45 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $1.9M5,211 at $364.31 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $1.2M3,176 at $365.26 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $440K1,200 at $366.31 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $1,4684 at $367.00 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $4.9M13,695 at $359.32 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Contrasting PainReform (NASDAQ:PRFX) & BeOne Medicines (NASDAQ:ONC)ONC · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name John Oyler; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.